Table 2

Follow-up of the patients (n = 5): psychiatric symptoms, CD activity, and amino acidconcentrations [median (min-max)].

0 (baseline)

≥1<1.5 months1)

p-value2)

≥3 months

p-value2)


CBCL Total problems

34 (9–39)

21 (8–29)

**

21 (2–22)

**

YSR Total problems

20 (9–36)

11 (5–41)

n.s.

2 (0–22)

**

S-tTGAbA

42 (10–310)

5 (3–51)

**

3 (1–17)

**

Prolactin3)

1100 (635–2850)

256 (127–282)

n.s *

244 (110–565)

**

L-tyrosine4)

33 (26–44)

39 (37–70)

n.s *

40 (38–47)

**

CAA5)

353 (316–441)

401 (368–657)

n.s *

395 (367–568)

**

L-tryptophan4)

40 (32–51)

52 (45–66)

n.s *

46 (36–59)

n.s.

Tryptophan/CAA6)

11.3 (10.1–14.9)

12.0 (10.1–14.1)

n.s.

10.1 (9.5–12.5)

n.s.

Free L-tryptophan 4)

4.9 (4.5–11.8)

8.4 (5.3–10.9)

n.s *

10.6 (5.0–19.0)

n.s. * 7)

Free tryptophan/CAA6)

1.4 (1.0–3.5)

1.9 (1.0–3.0)

n.s.

2.6 (1.3–3.4)

n.s.


1) amino acid concentrations; n = 4; 2) Wilcoxon signed – ranks test: compared with baseline; ** = P < 0.05; * = P ≥ 0.05 < 0.07; 3) mU/l; normal: females 50–300, males 50–500; 4) pmol/μl; 5) L-valine, L-leucine, L-isoleucine, L-phenylalanine, L-tyrosine; pmol/μl; 6) 100 × pmol/μl: pmol/μl; 7) repeated Measures Friedman test, n = 4, P = 0.050

Pynnönen et al. BMC Psychiatry 2005 5:14   doi:10.1186/1471-244X-5-14

Open Data